FY2027 EPS Estimates for Pfizer Boosted by Erste Group Bank

Key Points

• Erste Group Bank slightly raised its FY2027 EPS estimate for Pfizer to $2.84 from $2.83, signaling modestly improved expectations for the company’s long-term earnings.
• Pfizer’s latest quarterly results topped estimates, with EPS of $0.75 versus $0.72 expected and revenue of $14.45 billion versus $13.84 billion expected, while revenue rose 5.4% year over year.
• The stock continues to draw attention for its high dividend yield of about 6.7%, even as analysts overall remain cautious with a Hold consensus rating and a $28.74 average price target.

Pfizer Inc. (NYSE:PFE - Free Report) - Erste Group Bank boosted their FY2027 earnings per share estimates for shares of Pfizer in a report released on Tuesday, May 5th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will earn $2.84 per share for the year, up from their previous estimate of $2.83. The consensus estimate for Pfizer's current full-year earnings is $2.98 per share.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business's revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS.

A number of other equities research analysts have also issued reports on PFE. Morgan Stanley upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company an "equal weight" rating in a research note on Friday, April 10th. Royal Bank Of Canada reissued an "underperform" rating and issued a $25.00 price objective on shares of Pfizer in a report on Monday, April 20th. BMO Capital Markets restated an "outperform" rating and set a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Daiwa Securities Group downgraded Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. Finally, Guggenheim lifted their target price on Pfizer from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $28.74.

Pfizer Price Performance

Shares of PFE stock opened at $25.65 on Monday. The firm has a market cap of $146.17 billion, a P/E ratio of 19.58 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer has a 1-year low of $21.97 and a 1-year high of $28.75. The firm has a fifty day moving average of $27.14 and a two-hundred day moving average of $26.16.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's dividend payout ratio is currently 131.30%.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently bought and sold shares of PFE. Norges Bank bought a new stake in shares of Pfizer in the 4th quarter worth approximately $1,830,986,000. Morgan Stanley boosted its position in Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares during the period. Bank of New York Mellon Corp grew its stake in Pfizer by 38.9% during the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company's stock worth $1,208,023,000 after buying an additional 13,581,757 shares during the last quarter. Franklin Resources Inc. increased its position in Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock worth $638,787,000 after buying an additional 8,108,887 shares during the period. Finally, Janus Henderson Group PLC increased its position in Pfizer by 577.5% in the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company's stock worth $218,817,000 after buying an additional 7,489,189 shares during the period. Institutional investors own 68.36% of the company's stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank initiated a Buy view on Pfizer, adding to recent analyst confidence in the stock. Pfizer (PFE) Receives a Buy from Scotiabank
• Positive Sentiment: Erste Group slightly raised its FY2026 EPS estimate for Pfizer, reinforcing expectations that earnings remain stable and in line with consensus.
• Positive Sentiment: Recent coverage highlighted Pfizer’s Q1 beat, better-than-expected sales, and progress in its oncology pipeline, suggesting the company’s newer drugs are becoming more important to the investment story. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer’s dividend remains a major draw for income investors, and a recent article argued that the high yield is still supported by management’s execution and cash flow. Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics
• Neutral Sentiment: Pfizer is continuing to advance a new Phase 1 cancer trial, which signals ongoing investment in oncology but is still too early to materially change near-term financial results. Pfizer’s New Phase 1 Cancer Trial Signals Fresh Oncology Push for PFE Investors
• Neutral Sentiment: Pfizer was also mentioned in a cancer-care industry recognition announcement, but the item is mostly reputational and unlikely to move the stock on its own.
• Negative Sentiment: Pfizer halted an early-stage cancer study, and investors may view the termination as a small setback for its oncology pipeline, even if the financial impact is limited. Pfizer Terminates Early-Stage Cancer Trial: What It Means for PFE Investors
• Negative Sentiment: Pfizer ended another early-stage lymphoma combination trial, which adds to concerns that some pipeline programs may not advance as hoped. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.